Imatinib shows increased survival in ICR ’s Phase III oncology trial
A Phase III clinical trial of imatinib (Glivec) conducted by UK researchers from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust demonstrated increased survival in patients with advanced gastrointestinal stromal tumo … (Source: Drug Development Technology)
Source: Drug Development Technology - August 20, 2017 Category: Pharmaceuticals Source Type: news

Cellectis starts dosing patients in UCART123 ’s Phase I trial for BPDCN
Biopharmaceutical firm Cellectis has started dosing patients in a Phase I clinical trial of its universal chimeric antigen receptor T-cell (UCART) product candidate UCART123 to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). (Source: Drug Development Technology)
Source: Drug Development Technology - August 20, 2017 Category: Pharmaceuticals Source Type: news

Medivir enrols first patient in combination trial for refractory solid tumours
Swedish pharmaceutical company Medivir has started patient enrolment in a Phase I/II clinical trial of its product candidate birinapant in combination with Merck ’s anti-PD-1 therapy Keytruda (pembrolizumab) for treatment-refractory solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - August 20, 2017 Category: Pharmaceuticals Source Type: news

Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)
Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - August 17, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: NicOx, FibroGen, Omeros
NicOx has announced the private placement of 3.5 million new ordinary shares priced at €7.5 ($8.85) each to raise €26.25m ($30.97m) in total. (Source: Drug Development Technology)
Source: Drug Development Technology - August 17, 2017 Category: Pharmaceuticals Source Type: news

Amgen ’s EBBINGHAUS trial of Repatha shows favourable outcome
Amgen has reported a favourable cognitive function outcome from Phase III EBBINGHAUS clinical trial of Repatha (evolocumab) currently being developed to minimise low-density lipoprotein (LDL) levels. (Source: Drug Development Technology)
Source: Drug Development Technology - August 17, 2017 Category: Pharmaceuticals Source Type: news

M & As this week: Evotec, BioreclamationIVT
German pharmaceutical research company Evotec has acquired US-based drug discovery and development company Aptuit for $300m. (Source: Drug Development Technology)
Source: Drug Development Technology - August 17, 2017 Category: Pharmaceuticals Source Type: news

TRACON Pharmaceuticals reports positive results from Phase Ib/II trial of HCC drug
TRACON Pharmaceuticals has reported positive results from the National Cancer Institute (NCI) Phase Ib/II clinical trial of TRC105 and Nexavar (sorafenib) to treat patients with hepatocellular cancer (HCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 17, 2017 Category: Pharmaceuticals Source Type: news

Achieve begins cytisine ’s clinical programme for smoking cessation
Achieve Life Sciences has initiated the Cytisine Clinical Development Programme in the US to evaluate the product candidate as a form of treatment for smoking cessation. (Source: Drug Development Technology)
Source: Drug Development Technology - August 16, 2017 Category: Pharmaceuticals Source Type: news

Lexicon announces additional positive Phase III data for diabetes drug
Lexicon Pharmaceuticals has reported additional positive data from its Phase III inTandem2 clinical trial of sotagliflozin in adult type 1 diabetes patients on a background of optimised insulin. (Source: Drug Development Technology)
Source: Drug Development Technology - August 16, 2017 Category: Pharmaceuticals Source Type: news

Iovance commences LN-145 dosing in Phase II trial for cervical cancer
US-based biotechnology firm Iovance Biotherapeutics has commenced patient dosing in its Phase II C-145-04 clinical trial of LN-145 to treat recurrent, metastatic or persistent cervical carcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 16, 2017 Category: Pharmaceuticals Source Type: news

Researchers demonstrate use of breast cancer drug to shrink brain tumours
Researchers from the University of Queensland ’s Institute for Molecular Bioscience in Australia and the Fred Hutchinson Cancer Research Centre in the US have conducted a clinical trial to evaluate a previously approved breast cancer drug palbociclib … (Source: Drug Development Technology)
Source: Drug Development Technology - August 15, 2017 Category: Pharmaceuticals Source Type: news

BMS Phase III ’s combination trial for RCC meets one co-primary endpoint
Bristol-Myers Squibb (BMS) has reported top-line results from the Phase III CheckMate -214 clinical trial of Opdivo (nivolumab) and Yervoy (ipilimumab) combination to treat advanced or metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 15, 2017 Category: Pharmaceuticals Source Type: news

Vyriad and Sanford Health begin Phase I viro-immunotherapy trial
US-based biopharmaceutical firm Vyriad has initiated a clinical trial at integrated health system Sanford Health to evaluate a genetically engineered virus for destroying therapy-resistant tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - August 15, 2017 Category: Pharmaceuticals Source Type: news

University of Southampton investigates Acerta ’s lymphoma drug
Researchers at the University of Southampton, UK, have initiated a clinical trial to evaluate Acerta Pharma ’s new product candidate acalabrutinib in combination with existing standard therapy called R-CHOP to treat select patients with diffuse large … (Source: Drug Development Technology)
Source: Drug Development Technology - August 14, 2017 Category: Pharmaceuticals Source Type: news